Mon 8 Nov 2010
Reforming America’ Healthcare System
Posted by Helen Evans under Announcements, Book review, US Healthcare Reforms
No Comments

I have a chapter on Comparative Effectiveness in this this new publication by the Hoover Institution. In it I discuss the problems faced by Western Europe from government led Health Technology Assessment describing lessons learned from such institutions as NICE in the UK that has denied women with breast cancer Herceptin, people with Altzheimer’s disease Aricept and MS patients Beta Interferon to name but a few.
I suggest the following three courses of for America;
- America should reject the statutory creation of any organization that seeks to centralize government control of patient access to drugs, devices, medical technologies, treatments or procedures.
- Comparative Effectiveness research in healthcare and health technology assessments should be undertaken only by the private sector and not governmental bodies.
- Comparative Effectiveness research should be patient-centered and supportive of quality and value, not focused simply on cost-containment. In this respect, it should promote scientific advances, health information technology, and the emerging science of personalized medicine.
I conclude;
As is clear from the British experience and other example from Western Europe, a comparative effectiveness strategy that relies on central planing and coercion will not only be counterproductive in the long run – because it will undermine the incentives for medical innovation – but it will also lead to the imposition of cost constraints that will worsen patients’ medical conditions and damage the quality of their lives.
Those with an interest in the provision and funding of healthcare should definitely add
The time has come for me to share with you another paper that I found invaluable while studying for my PhD.






